Human anti-CD40 antibodies
AssigneesGemini Science, Inc., La Jolla Institute for Allergy and Immunology
InventorsToshifumi Mikayama, Nobuaki Takahashi, Xingjie Chen, Stephen P. Schoenberger
Life of this patent
Estimating the term…
Abstract
The invention is directed to human antibodies that bind CD40 (e.g., human CD40), methods of producing the antibodies and methods of use. Invention human CD40 antibodies include antibodies that can modulate one or more activities of CD40, such as increasing or decreasing cell proliferation. Invention human CD40 antibodies are therefore useful for increasing or decreasing a CD40 activity in order to alter CD40 activity in vivo.
Claims30
A human monoclonal antibody or a CD40-binding fragment thereof, wherein the antibody is denoted number 11, which is produced by hybridoma ATCC PTA-2308.
A human monoclonal antibody, wherein the antibody comprises the heavy-chain variable sequence and the light-chain variable sequence of the antibody denoted as number 11, which is produced by hybridoma ATCC PTA-2308.
A human monoclonal antibody, wherein the antibody comprises the heavy-chain valuable sequence and the light-chain variable sequence encoded by the pair of sequences set forth as SEQ ID NO:
- 10 and SEQ ID NO:
- 11;
- SEQ ID NO:
- 12 and SEQ ID NO:
- 13;
- or SEQ ID NO:
- 14 and SEQ ID NO:
- 15.
A human monoclonal antibody, wherein the antibody comprises a heavy-chain variable sequence and a light-chain valuable sequence encoded by heavy and light chain sequences selected from F2-103-heavy chain (ATCC PTA-3302) and F2-103-light chain (ATCC PTA-3303);
- F5-77-heavy chain (ATCC PTA-3304) and F5-77-light chain (ATCC PTA-3305);
- and F5-157-heavy chain (ATCC PTA-3306) and F5-157-light chain (ATCC PTA-3307).
A hybridoma denoted as ATCC PTA-2308.
A hybridoma denoted as ATCC PTA-2309.
A hybridoma denoted as ATCC PTA-3337.
A hybridoma denoted as ATCC PTA-3338.
A cell line denoted as ATCC PTA-3302.
A cell line denoted as ATCC PTA-3303.
A cell line denoted as ATCC PTA-3304.
A cell line denoted as ATCC PTA-3305.
A cell line denoted as ATCC PTA-3306.
A cell line denoted as ATCC PTA-3307.
A human monoclonal antibody or a CD40-binding fragment thereof, wherein the antibody is denoted number 72, which is produced by hybridoma ATCC PTA-2309.
A human monoclonal antibody or a CD40-binding fragment thereof, wherein the antibody produced by a hybridoma denoted as F1-102 (ATCC PTA-3337).
A human monoclonal antibody or a CD40-binding fragment thereof, wherein the antibody produced by a hybridoma denoted as F4-465 (ATCC PTA-3338).
A human monoclonal antibody or a CD40-binding fragment thereof, wherein the antibody is denoted as F2-103, in which heavy chain of the antibody is produced by ATCC PTA-3302, and in which light chain of the antibody is produced by ATCC PTA-3303.
A human monoclonal antibody or a CD40-binding fragment thereof, wherein the antibody is denoted as F5-17, in which the heavy chain of the antibody is produced by ATCC PTA-3304, and in which the light chain of the antibody is produced by ATCC PTA-3305.
A human monoclonal antibody or a CD40-binding fragment thereof, wherein the antibody is denoted as F5-157, in which the heavy chain of the antibody is produced by ATCC PTA-3306, and, in which the light chain of the antibody is produced by ATCC PTA-3307.
A human monoclonal antibody, wherein the antibody comprises the heavy-chain variable sequence and the light-chain variable sequence of the antibody denoted as number 72, which is produced by hybridoma ATCC PTA-2309.
A human monoclonal antibody, wherein the antibody comprises the heavy-chain variable sequence and the light-chain variable sequence of the antibody produced by a hybridoma denoted as F1-102(ATCC PTA-3337).
A human monoclonal antibody, wherein the antibody comprises the heavy-chain variable sequence and the light-chain variable sequence of the antibody produced by a hybridoma denoted as F4-465 (ATCC PTA-3338).
Dependencies are inferred from the claim text.